IL17A and anemia: These factors include anemia [9], a white blood cell (WBC) count in the cerebrospinal fluid (CSF) above 20 cells/mm3 [10], failure to respond to first-line immunotherapy, and high-interleukin-17A (IL-17A) concentrations in the CSF [11, 12].